Technology

U.S. patent law will have to adapt to the use of AI in the life sciences industry.

The technology is not just about digital enablement anymore.

Jason Smith discusses his work with AI-based data platforms.

Anderson speaks about his work with new technology and platforms.

New MMIT research highlights payers’ continued hesitancy toward PDTs. Here’s what manufacturers need to know.

Automated risk management and improved regulatory compliance among opportunities offered by case collection.

Addressing sources of tension on differentiating types of data.

Recent advances from COVID-19 vaccine development put pharma in place to further grow relationship with patients.

With more promising products emerging, investment risks remain.

Hill shares her insights on what is needed for a turnaround in talent development.

Despite the rapid innovation of machine learning, correct protocols to ensure compliance and trustworthiness must be considered.

From exposing disparities in care to guiding better patient outcomes to helping reign in the costs of care, the use of real-world data (RWD) in oncology can have far-reaching effects. Here’s how one RWD company exec is using her experience to help drive that change.

What’s next and lasting in engagement for medical affairs and commercial teams isn’t complicated, but a big shift is here to stay, according to analysis of an industry survey.

Continued push for latest technology in biopharma will advance collection of patient data.

Genomic data is transforming precision medicine—but progress depends on it being easily available where it’s needed. Pharmaceutical Executive speaks to Ignacio Medina, founder of Cambridge University spinout Zetta Genomics, to see how next-generation open-source data technologies accelerate discovery in the lab and patient benefit in the clinic.

Rush shares his thoughts on how advanced analytics are making their mark on the pharma industry.

A new report examining pharma sector exposure makes for sobering reading, especially in US.

Obstacles in data exchange remain for industry.

Digital disruption is poised to usher in a new era of customer-centricity and efficiency, starting with trials and precision targeting.

Designing an omnichannel artificial intelligence ecosystem that integrates strategies can boost commercial success for pharma.

Spurred on by COVID-19 and companies’ evolving digital maturity, AI looks set to gain a real foothold in pharma’s promotional activities.

Providing ultimate value to stakeholders remains key in new style of development.

Scott Swain details the most common roadblocks that pharma companies experience when incorporating real-world data (RWD) in regulatory submissions and looks at how they can be addressed.

As emerging technologies are identified, C-suites need to determine how they might be pragmatically deployed as solutions to address their pain points, says IBM‘s Dr. Bernard S. Meyerson.